Mother to child transmission of HIV-1 in a Thai population: Role of virus characteristics and maternal humoral immune response

Journal of Medical Virology

Volumn 81, Issue 5, 2009, Pages 768-778

  Kittinunvorakoon, Chonticha ^a,b   Morris, Mary Kate ^b   Neeyapun, Kanchana ^c   Jetsawang, Bongkoch ^c   Buehring, Gertrude C ^a   Hanson, Carl V ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

^c MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

HIV; Humoral immune response; Mother to child transmission; Replication kinetics

Indexed keywords

CHEMOKINE RECEPTOR CCR5; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ARTICLE; BABY; BIRTH; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMORAL IMMUNITY; LYMPHOCYTE; MAJOR CLINICAL STUDY; MOTHER; PHENOTYPE; RISK FACTOR; SPECIES DIVERSITY; THAILAND; VERTICAL TRANSMISSION; VIRUS CHARACTERIZATION; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; KINETICS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; THAILAND; VIRUS REPLICATION; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 65649104425     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21465     Document Type: Article

References (67)

1. Amornwichet P, Teeraratkul A, Simonds RJ, Naiwatanakul T, Chantharojwong N, Culnane M, Tappero JW, Kanshana S. 2002. Preventing mother-to-child HIV transmission: The first year of Thailand's national program. J Am Med Assc 288:245-248.
2. Arroyo MA, Tien H, Pagan M, Swanstrom R, Hillyer GV, Cadilla CL, Melendez-Guerrero LM. 2002. Virologic risk factors for vertical transmission of HIV type 1 in Puerto Rico. AIDS Res Hum Retroviruses 18:447-460.
3. Asjo B, Morfeldt-Manson L, Albert J, Biberfeld G, Karlsson A, Lidman K, Fenyo EM. 1986. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 2:660-662.
4. Barin F, Jourdain G, Brunet S, Ngo-Giang-Huong N, Weerawatgoompa S, Karnchanamayul W, Ariyadej S, Hansudewechakul R, Achalapong J, Yuthavisuthi P, Ngampiyaskul C, Bhakeecheep S, Hemwutthiphan C, Lallemant M. 2006. Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1. J Infect Dis 193:1504-1511.
5. Barouch DH. 2008. Challenges in the development of an HIV-1 vaccine. Nature 455:613-619.
6. Beddows S, Louisirirotchanakul S, Cheingsong-Popov R, Easterbrook PJ, Simmonds P, Weber J. 1998. Neutralization of primary and Tcell line adapted isolates of human immunodeficiency virus type 1: Role of V3-specific antibodies. J Gen Virol 79:77-82.
7. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA. 1998. A new classification for HIV-1. Nature 391:240.
8. Bongertz V, Costa CI, Veloso VG, Grinsztejn B, Joao Filho EC, Calvet G, Pilotto JH, Guimaraes ML, Morgado MG. 2001. Vertical HIV-1 transmission: Importance of neutralizing antibody titer and specificity. Scand J Immunol 53:302-309.
9. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-Van Dillen PM, Van der Noordaa J. 1990. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28:495-503.
10. Boom R, Sol C, Beld M, Weel J, Goudsmit J, Wertheim-van Dillen P. 1999. Improved silica-guanidiniumthiocyanate DNA isolation procedure based on selective binding of bovine alpha-casein to silica particles. J Clin Microbiol 37:615-619.
11. Boyer V, Desgranges C, Trabaud MA, Fischer E, Kazatchkine MD. 1991. Complementmediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion. J Exp Med 173:1151-1158.
12. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Conway B, Lalonde R, Sekaly RP. 2002. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 76:1753-1761.
13. Brown BK, Wieczorek L, Sanders-Buell E, Rosa Borges A, Robb ML, Birx DL, Michael NL, McCutchan FE, Polonis VR. 2008. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 375:529-538.
14. Calarota SA, Libonatti OV. 2000. Maternal antibodies to HIV-1 envelope domains: No correlation with HIV-1 vertical transmission in patients from Argentina. Scand J Immunol 52:292-297.
15. CDC. 1997. 1997 revised guidelines for performing CD4+ T-cell determinations in persons infected with human immunodeficiency virus (HIV). Centers for Disease Control and Prevention. MMWR Recomm Rep 46:1-29.
16. Cheng-Mayer C, Seto D, Tateno M, Levy JA. 1988. Biologic features of HIV-1 that correlate with virulence in the host. Science 240:80-82.
17. Chuachoowong R, Shaffer N, VanCott TC, Chaisilwattana P, Siriwasin W, Waranawat N, Vanprapar N, Young NL, Mastro TD, Lambert JS, Robb ML. 2000. Lack of association between human immunodeficiency virus type 1 antibody in cervicovaginal lavage fluid and plasma and perinatal transmission, in Thailand. J Infect Dis 181:1957-1963. (Pubitemid 30416157)
18. Connor RI, Ho DD. 1994. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol 68:4400-4408.
19. Delwart EL, Herring B, Rodrigo AG, Mullins JI. 1995. Genetic subtyping of human immunodeficiency virus using a heteroduplex mobility assay. PCR Methods Appl 4:S202-S216.
20. Devash Y, Calvelli TA, Wood DG, Reagan KJ, Rubinstein A. 1990. Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. Proc Natl Acad Sci USA 87:3445-3449.
21. Dickover R, Garratty E, Yusim K, Miller C, Korber B, Bryson Y. 2006. Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J Virol 80:6525-6533.
22. Doms RW, Trono D. 2000. The plasma membrane as a combat zone in the HIV battlefield. Genes Dev 14:2677-2688.
23. Eshelman SH, Lie Y, Hoover DR, Chen S, Hudelson SE, Fiscus SA, Petropoulus CJ, Kumwenda N, Parkin N, Taha TE. 2006. Association between the replication capacity and mother-to-child transmission of HIV-1, in antiretroviral drug-naïve Malawian women. J Infect Dis 193:1512-1515.
24. European collaborative study. 2001. HIV-infected pregnant women and vertical transmission in Europe since1986.European collaborative study. AIDS 15:761-770.
25. Goedert JJ, Mendez H, Drummond JE, Robert-Guroff M, Minkoff HL, Holman S, Stevens R, Rubinstein A, Blattner WA, Willoughby A, Landesman SH. 1989. Mother-to-infant transmission of human immunodeficiency virus type 1: Association with prematurity or low anti-gp120. Lancet 2:1351-1354.
26. Guevara H, Casseb J, Zijenah LS, Mbizvo M, Oceguera LF III, Hanson CV, Katzenstein DA, Hendry RM. 2002. Maternal HIV-1 antibody and vertical transmission in subtype C virus infection. J Acquir Immune Defic Syndr 29:435-440.
27. Hanson CV, Crawford-Miksza L, Sheppard HW. 1990. Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers. J Clin Microbiol 28:2030-2034.
28. Hollinger FB, Bremer JW, Myers LE, Gold JW, McQuay L. 1992. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories. J Clin Microbiol 30:1787-1794.
29. Husson RN, Lan Y, Kojima E, Venzon D, Mitsuya H, McIntosh K. 1995. Vertical transmission of human immunodeficiency virus type 1: Autologous neutralizing antibody, virus load, and virus phenotype. J Pediatr 126:865-871.
30. Jackson JB, Coombs RW, Sannerud K, Rhame FS, Balfour HH, Jr. 1988. Rapid and sensitive viral culture method for human immunodeficiency virus type 1. J Clin Microbiol 26:1416-1418.
31. Johnston ER, Zijenah LS, Mutetwa S, Kantor R, Kittinunvorakoon C, Katzenstein DA. 2003. High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol 77:7682-7688.
32. Kliks SC, Wara DW, Landers DV, Levy JA. 1994. Features of HIV-1 that could influence maternal-child transmission. J Am Med Assc 272:467-474.
33. Konings FA, Burda ST, Urbanski MM, Zhong P, Nadas A, Nyamba PN. 2006. Human immunodeficiency virus type 1 (HIV-1) circulating recombinant form 02-AG (CRF02-AG) has a higher in vitro replicative capacity than its parental subtypes A and G. J Med Virol 78:523-534.
34. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, Miedema F, Schellekens PT, Tersmette M. 1993. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 118:681-688.
35. Kwa D, Vingerhoed J, Boeser B, Schuitemaker H. 2003. Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. J Infect Dis 187:1397-1403.
36. Lallemant M, Baillou A, Lallemant-LeCoeur S, Nzingoula S, Mampaka M, M'Pele P, Barin F, Essex M. 1994. Maternal antibody response at delivery and perinatal transmission of human immunodeficiency virus type 1 in African women. Lancet 343:1001-1005.
37. Lantz MA, Falcone VH. 1968. The necessity for heating sera for the VDRL slide test. Am J Med Technol 24:551-556.
38. Lathey JL, Tsou J, Brinker K, Hsia K, Meyer WA III, Spector SA. 1999. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. J Infect Dis 180:344-350.
39. Louisirirotchanakul S, Beddows S, Cheingsong R, Shaffer N, Mastro TD, Likanonsakul S, Wasi C, Taylor GP, Weber JN. 1999. Role of maternal humoral immunity in vertical transmission of HIV-1 subtype E in Thailand. J Acquir Immune Defic Syndr 21:259-265.
40. Mabondzo A, Rouvier P, Raoul H, Le Naour R, Courpotin C, Herve F, Parnet-Mathieu F, Lasfargues G, Dormont D. 1995. Relationships between humoral factors in HIV-1-infected mothers and the occurrence of HIV infection in their infants. Clin Exp Immunol 102:476-480.
41. Martinez-Picado J, Martinez MA. 2008. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo. Virus Res 134:104-123.
42. Mock PA, Shaffer N, Bhadrakom C, Siriwasin W, Chotpitayasunondh T, Chearskul S, Young NL, Roongpisuthipong A, Chinayon P, Kalish ML, Parekh B, Mastro TD. 1999 Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. AIDS 13:407-414.
43. Mofenson LM. 1997. Mother-child HIV-1 transmission: Timing and determinants. Obstet Gynecol Clin North Am 24:759-784.
44. Moog C, Fleury HJ, Pellegrin I, Kirn A, Aubertin AM. 1997. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 71:3734-3741.
45. Morris MK, Katzenstein DA, Israelski D, Zolopa A, Hendry RM, Hanson CV. 2001. Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 28:405-415.
46. Ometto L, Zanotto C, Maccabruni A, Caselli D, Truscia D, Giaquinto C, Ruga E, Chieco-Bianchi L, De Rossi A. 1995. Viral phenotype and host-cell susceptibility to HIV-1 infection as risk factors for mother-to-child HIV-1 transmission. AIDS 9:427-434.
47. Pancino G, Leste-Lasserre T, Burgard M, Costagliola D, Ivanoff S, Blanche S, Rouzioux C, Sonigo P. 1998. Apparent enhancement of perinatal transmission of human immunodeficiency virus type 1 by high maternal anti-gp160 antibody titer. J Infect Dis 177:1737-1741.
48. Parekh BS, Shaffer N, Pau CP, Abrams E, Thomas P, Pollack H, Bamji M, Kaul A, Schochetman G, Rogers M, George RJ, The NYC Rerinatal HIV Transmission Collaborative Study. 1991. Lack of correlation between maternal antibodies to V3 loop peptides of gp120 and perinatal HIV-1 transmission. The NYC Perinatal HIV Transmission Collaborative Study. AIDS 5:1179-1184.
49. Pau CP, Lee-Thomas S, Auwanit W, George JR, Ou CY, Parekh BS, Granade TC, Holloman DL, Phillips S, Schochetman G, Young N, Takebe Y, Gayle HD, Weniger BG. 1993. Highly specific V3 peptide enzyme immunoassay for serotyping HIV-1 specimens from Thailand. AIDS 7:337-340.
50. Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, Zhou JT, Bolognesi DP, Fauci AS, Montefiori DC. 1997. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 176:924-932.
51. Poirier MC, Olivero OA, Walker DM, Walker VE. 2004. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol 199:151-161.
52. Polonis VR, Brown BK, Rosa Borges A, Zolla-Pazner S, Dimitrov DS, Zhang MY, Barnett SW, Ruprecht RM, Scarlatti G, Fenyö EM, Montefiori DC, McCutchan FE, Michael NL. 2008. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 375:315-320.
53. Richman DD, Bozzette SA. 1994. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 169:968-974.
54. Rossi P, Moschese V. 1991. Mother-to-child transmission of human immunodeficiency virus. FASEB J 5:2419-2426.
55. Scarlatti G, Albert J, Rossi P, Hodara V, Biraghi P, Muggiasca L, Fenyo EM. 1993. Mother-to-child transmission of human immunodeficiency virus type 1: Correlation with neutralizing antibodies against primary isolates. J Infect Dis 168:207-210.
56. Shaffer N, Chauchoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, Chotpitayasunondh T, Chearskul S, Roongpisuthipong A, Chinayon P, Karon J, Mastro TD, Simonds RJ. 1999a. Shortcourse Zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial. Lancet 353:773-780. (Pubitemid 29157640)
57. Shaffer N, Roongpisuthipong A, Siriwasin W, Chotpitayasunondh T, Chearskul S, Young N, Parekh BS, Mock PA, Bhadrakom C, Chinayon P, Kalish ML, Phillips SK, Granade TC, Subbarao S, Weniger BG, Mastro TD. 1999b. Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. J Infect Dis 179:590-599. (Pubitemid 30016142)
58. St Louis ME, Pau CP, Nsuami M, Ou CY, Matela B, Kashamuka M, Brown C, George JR, Heyward WL. 1994. Lack of association between anti-V3 loop antibody and perinatal HIV-1 transmission in Kinshasa, Zaire, despite use of assays based on local HIV-1 strains. J Acquir Immune Defic Syndr 7:63-67.
59. Sutthent R, Chokephaibulkit K, Piyasujabul D, Vanprapa N, Roogpisuthipong A, Chaisilwatana P. 2002. Effect of perinatal short-course zidovudine on the clinical and virological manifestations of HIV-1 subtype E infection in infants. J Clin Virol 25:47-56.
60. Taechowisan T, Sutthent R, Louisirirotchanakul S, Puthavathana P, Wasi C. 1996. V3 peptide enzyme immunoassay for serotyping HIV-1 infected pregnant Thais. Asian Pac J Allergy Immunol 14:121-123.
61. Tscherning-CasperC,VodrosD,MenuE,AperiaK,FredrikssonR,DolciniG,ChaouatG, Barre-SinoussiF,AlbertJ,FenyoEM.2000.CoreceptorusageofHIV- 1isolatesrepresentingdifferentgeneticsubtypesobtainedfrompregnant Cameroonianwomen.EuropeanNetworkforInUteroTransmissionofHIV-1. JAcquirImmuneDeficSyndr24:1-9.(Pubitemid30447800)
62. Ugen KE, Goedert JJ, Boyer J, Refaeli Y, Frank I, Williams WV, Willoughby A, Landesman S, Mendez H, Rubinstein A, Kieber- Emmons T, Weiner DB. 1992. Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. J Clin Invest 89:1923-1930.
63. UNAIDS. 1998. Connecting lower HIV infection rates with changes in sexual behavior in Thailand: Data collection and comparison. http:// data.unaids.org/Publications/IRC-pub03/HIV-behaviours-en.pdf? preview=true.
64. Weniger BG, Takebe Y, Ou CY, Yamazaki S. 1994. The molecular epidemiology of HIV in Asia. AIDS 8:S13-S28.
65. Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, Mbori- Ngacha D, Rainwater SMJ, Overbaugh J. 2006. Neutralization escape variants of Human Immunodeficiency Virus Type 1 are transmitted from mother to infant. J Virol 80:835-844.
66. Zolla-Pazner S. 1996. Mechanisms contributing to the neutralization of HIV-1. Immunol Lett 51:89-93.
67. Zolla-Pazner S. 2005. Improving on nature: Focusing the immune response on the V3 loop. Hum Antibodies 14:69-72.